Neurological disease progression in adults with ataxia-telangiectasia: a longitudinal study
Brain · 2026
DOI: 10.1093/brain/awag285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2026. Verfasst von Anke Hensiek und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0SR, UK. Hauptthemen laut MEDLINE: Ataxia Telangiectasia, Disease Progression, Nervous System Diseases. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Muscular Dystrophy UK, LifeArc Centre to Treat Mitochondrial Diseases, Hereditary Neuropathy Foundation.
Abstract (Originalsprache)
Ataxia-telangiectasia (AT) is a rare, multisystem neurodegenerative disorder with marked clinical heterogeneity. Longitudinal data on neurological progression remain limited, restricting understanding of disease mechanisms and therapeutic trial design. We analysed longitudinal Scale for the Assessment and Rating of Ataxia (SARA) data from the largest published adult AT cohort to date (n = 82, age > 16 years). Linear mixed-effects models were used to estimate severity at the earliest available neurological evaluation (baseline) and annual progression rates (points/year) in classic and variant AT, and to examine clinical and genetic modifiers. Neurological impairment progressed with a mean SARA increase of 0.38 points/year. Adults with classic AT were more severely affected than those with variant AT, with SARA scores approximately 8–9 points higher at baseline. However, neurological progression in adulthood was similar between classic and variant AT (0.33 versus 0.41 points/year), which includes 15 individuals with the antisense oligonucleotide targetable c.5763-1050A>G variant. Although AT subtypes differ substantially in childhood and adolescence, neurological decline converges to a similar pace in adulthood, irrespective of subtype or genotype. SARA remains a useful outcome measure but may underestimate progression in advanced disease and non-cerebellar domains. These findings inform counselling, prognostication and the design of interventional trials, including mutation-specific therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0SR, UK.
- National Clinic for Adults with Ataxia Telangiectasia, Papworth Hospital, Cambridge CB2 0AY, UK.
- Department of Genomic Medicine, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0QQ, UK.
- MRC Biostatistics Unit, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0SR, UK.
ORCID-Profile: May Yung Tiet, Rita Horvath
Förderung
- Muscular Dystrophy UK
- LifeArc Centre to Treat Mitochondrial Diseases
- Hereditary Neuropathy Foundation
- Wellcome Trust
- Cambridge Biomedical Research Centre
- Action for AT
- AFM-Telethon
- Marmaduke Sheild Fund
Zitieren
APA
Hensiek, A., Bottolo, L., Tiet, M. Y., Harrison, E., Ashby, E., Olympio, C., Biggs, H., Everett, N., Schon, K., & Horvath, R. (2026). Neurological disease progression in adults with ataxia-telangiectasia: a longitudinal study. Brain. https://doi.org/10.1093/brain/awag285
Vancouver
Hensiek A, Bottolo L, Tiet MY, Harrison E, Ashby E, Olympio C, et al. Neurological disease progression in adults with ataxia-telangiectasia: a longitudinal study. Brain. 2026. doi:10.1093/brain/awag285
BibTeX
@article{Hensiek2026,
author = {Hensiek, Anke and Bottolo, Leonardo and Tiet, May Yung and Harrison, Emma and Ashby, Elizabeth and Olympio, Catarina and Biggs, Heather and Everett, Natasha and Schon, Katherine and Horvath, Rita},
title = {Neurological disease progression in adults with ataxia-telangiectasia: a longitudinal study},
journal = {Brain},
year = {2026},
doi = {10.1093/brain/awag285}
}
EUVIMED